Lemonade, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lemonade, Inc. on April 26, 2021, reporting events that occurred on April 21, 2021. The filing addresses significant changes to the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
On April 21, 2021, the following changes to the Board of Directors took effect immediately:
- Resignations: G. Thompson Hutton (Class III) and Haim Sadger (Class II) tendered their resignations.
- Appointments: Silvija Martincevic and Irina Novoselsky were appointed to fill the vacant seats.
- Committee Assignments:
- Martincevic joined the Compensation Committee (replacing Sadger) and the Nominating and Corporate Governance Committee (replacing Hutton).
- Novoselsky joined the Audit Committee (replacing Hutton) and was appointed Chair of the Audit Committee.
Compensation and Governance Details
The new directors are subject to the Non-Employee Director Compensation Policy, which includes:
- Cash Retainers: $30,000 annual base retainer. Martincevic receives an additional $5,000 for the Compensation Committee. Novoselsky receives an additional $20,000 for Chairing the Audit Committee.
- Initial Equity Award: A grant of Restricted Stock Units (RSUs) valued at $175,000, vesting in equal annual installments over three years.
- Annual Equity Award: Future grants of RSUs valued at $150,000 following each annual meeting, vesting on the first anniversary.
- Deferred Compensation: Eligibility to participate in the Deferred Compensation Plan regarding settlement timing of RSU awards.
Key Facts for Investor Verification
- Verify the specific vesting schedules and performance conditions attached to the $175,000 initial RSU grants for Martincevic and Novoselsky.
- Confirm the total number of authorized shares available for issuance under the Company's equity incentive plans to assess dilution impact.
- Review the biographies of the new directors to understand their specific expertise relative to the Company's insurance and technology operations.
- Check subsequent filings for any changes to the Audit Committee Chair role or further board composition adjustments.